J&J’s Intra‑Cellular buyout, BMS’ oncology gambit, Sanofi’s Blueprint acquisition drive mega deals in H1 2025

Data Compilation
#PharmaFlow

Pipeline Prospector May 2025: Pfizer strikes US$ 6 bn oncology pact; Lilly diversifies pipeline with US$ 2.3 bn in deals

Stock Recap
#PipelineProspector

Famciclovir

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

35 API Suppliers, 11 USDMF, 5 JDMF, 5 EU WC, 14 KDMF, 8 NDC API, 14 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

18 Drugs in Development

18 Drugs in Development

INTERMEDIATES

1 Intermediate Suppliers

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

121 FDF Dossiers, 27 FDA Orange Book, 45 Europe, 9 Canada, 26 Australia, 6 South Africa, 8 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 125MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 Minakem, 2 SPI Pharma, 12 DKSH, 4 Faran Shimi Pharmaceutical, 5 Boai NKY Pharmaceuticals Ltd, 6 Gangwal Healthcare, 5 Nanjing Well Pharmaceutical, 1 Shanghai Minbiotech, 1 ACG Worldwide, 5 Actylis, 1 Alcedo Pharmachem, 9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 3 Ashland, 28 BASF, 1 Clariant, 10 Corel Pharma Chem, 7 DFE Pharma, 2 Esteem Industries, 1 Finar, 12 Gangwal Chemicals, 4 Ideal Cures, 2 Ingredion Pharma Solutions, 36 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 15 Microlex e.U, 2 Nanjing Bold Chemical, 3 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 3 Novo Excipients, 5 Pharmatrans-Sanaq, 4 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 15 Roquette, 12 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 10 Sigachi Industries, 4 Silverline Chemicals, 2 The Dow Chemical Company, 1 Ulanqab Kema New Material, 4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

66 Fillers, Diluents & Binders, 46 Coating Systems & Additives, 38 Disintegrants & Superdisintegrants, 28 Solubilizers, 28 Thickeners and Stabilizers, 26 Granulation, 26 Direct Compression, 26 Controlled & Modified Release, 22 Lubricants & Glidants, 17 Topical, 16 Co-Processed Excipients, 14 Film Formers & Plasticizers, 10 Parenteral, 8 Emulsifying Agents, 8 Chewable & Orodispersible Aids, 7 Rheology Modifiers, 5 Empty Capsules, 5 API Stability Enhancers, 4 Vegetarian Capsules, 4 Taste Masking, 4 Coloring Agents, 3 Surfactant & Foaming Agents

DIGITAL CONTENT

5 News #PharmaBuzz

5 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 62 Regulatory FDF Prices

MARKET PLACE

3 APIs

3 APIs

PATENTS & EXCLUSIVITIES

13 Health Canada Patents

13 Health Canada Patents

REF. STANDARDS & IMPURITIES

7 Others

7 Others

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	Registration No.	Compound	Registration Date	Manufacturer	Manufacturer's Country	Manufacturer's Address
28/06/2025	CHANGZHOU KONY PHARMACEUTICAL CO., LTD. CN 213 105 Changzhou	China	Kosha Bio Co., Ltd.	20180208-209-J-153(4)	Palmciclovir	2019-01-24	Changzhou Kony Pharmaceutical Co.,Ltd.	China	Daixi Street, Luoyang Town, Wujin District, Changzhou, Jiangsu China
28/06/2025	Charioteer	China	Huseeed Co., Ltd.	20210303-209-J-743(2)	Famciclovir	2023-12-07	Zhejiang Charioteer Pharmaceutical Co., Ltd.	China	Tongyuanxi, Dazhan, Xianju, Zhejiang Province, 317321, PR China

Famciclovir

Famciclovir

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

35 API Suppliers

11 USDMF

5 JDMF

5 EU WC

14 KDMF

8 NDC API

14 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

18 Drugs in Development

INTERMEDIATES

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

121 FDF Dossiers

27 FDA Orange Book

45 Europe

9 Canada

26 Australia

6 South Africa

8 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 125MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 Minakem

2 SPI Pharma

12 DKSH

4 Faran Shimi Pharmaceutical

5 Boai NKY Pharmaceuticals Ltd

6 Gangwal Healthcare

5 Nanjing Well Pharmaceutical

1 Shanghai Minbiotech

1 ACG Worldwide

5 Actylis

1 Alcedo Pharmachem

9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

3 Ashland

28 BASF

1 Clariant

10 Corel Pharma Chem

7 DFE Pharma

2 Esteem Industries

1 Finar

12 Gangwal Chemicals

4 Ideal Cures

2 Ingredion Pharma Solutions

36 Kerry

3 Kima Chemical

6 Lonza Capsugel

15 Microlex e.U

2 Nanjing Bold Chemical

3 Nitika Pharmaceutical Specialities

2 Nomisma Healthcare

3 Novo Excipients

5 Pharmatrans-Sanaq

4 Pluviaendo

4 Prachin Chemical

1 Qianhao Chemical (Hebei) Co., Ltd

1 Qualicaps

15 Roquette

12 Seppic

4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

10 Sigachi Industries

4 Silverline Chemicals

2 The Dow Chemical Company

1 Ulanqab Kema New Material

4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

66 Fillers, Diluents & Binders

46 Coating Systems & Additives

38 Disintegrants & Superdisintegrants

28 Solubilizers

TABLET;ORAL - 125MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 250MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 500MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons